The role of the peptides in the selective delivery of anthracyclines for cancer cells

Doxorubicin (DOX ) and other anthracyclines are commonly used in the treatment of cancer, both leukemias and solid tumors. The clinical use of these drugs is limited by side effects , especially the cardiotoxicity , myelosuppression , or damage to the kidneys . Efforts are therefore numerous studies aimed at reducing the side effects and increase the efficacy of doxorubicin and other anthracyclines . One alternative strategy is the use of drugs conveyors , such as liposomes, dendrimers , or the antibody nanoparticles .

Aclarubicin - an alternative to anthracycline-resistant cells and generation

Aclarubicin is one of the derivatives of anthracycline drugs exhibiting less side effects in comparison with the commonly used anthracyclines Generation - doxorubicin and daunorubicin. This article presents the current knowledge of the molecular mechanisms of the cytotoxic effect of the ACL, such as the effect on the activity of topoisomerase I and II, the processes of replication and transcription. Also discussed was the impact of the ACL with the cell membrane, drug transport through the membrane and the plasma membrane involved in the acquisition of multidrug resistance.

The Editorial Board
Andrzej Łukaszyk - przewodniczący, Zofia Bielańska-Osuchowska, Szczepan Biliński, Mieczysław Chorąży, Aleksander Koj, Włodzimierz Korochoda, Leszek Kuźnicki, Aleksandra Stojałowska, Lech Wojtczak

Editorial address:
Katedra i Zakład Histologii i Embriologii Uniwersytetu Medycznego w Poznaniu, ul. Święcickiego 6, 60-781 Poznań, tel. +48 61 8546453, fax. +48 61 8546440, email:

PBK Postępby biologi komórki